Chinese startup NeuroXess' new BCI can decipher the complex Chinese language in brain, operate a robotic arm and interact with AI.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Chinese startup NeuroXess on Thursday reported two significant clinical-trial milestones its flexible brain-computer interface BCI device successfu ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

According to a report, brain-computer interface (BCI) technology lets patients control software, move objects, interact with ...

Large research symposium highlights liquid biopsies, new drug combos, shifts in surgical practice and, yes, patient voices.

随着我国老龄化社会的加深，肺癌的发病率在老年人群中不断上升，如何为这一特殊群体提供安全有效的治疗方案，成为了医学界亟待解决的问题。那么，在老年患者中，度伐利尤单抗的巩固治疗真的奏效吗？

此次获批主要基于III期MIRASOL 试验，2024年欧洲肿瘤内科学会（ESMO）上报告了该试验结果。共227例患者接受索米妥昔单抗，226例患者接受对照组治疗，结果显示：索米妥昔单抗组有97例患者肿瘤缩小或消失，其中13例患者达到完全缓解（CR） ...